Skip to main content
. 2023 May 30;7:e43385. doi: 10.2196/43385

Table 3.

Descriptive of intervention outcomes at preintervention, postintervention, and follow-up scheduled assessment time points by preintervention clinical diagnostic presentation subgroups.


Preintervention: week 0 (n=241) Postintervention: week 8 (n=58-61) 1-month follow-up: week 12 (n=41) 3-month follow-up: week 20 (n=34-35)

Values, n (%) Values, mean (SD) Values, n (%) Values, mean (SD) Values, n (%) Values, mean (SD) Values, n (%) Values, mean (SD)
GAD-7a

Anxiety 26 (10.8) 12.35 (3.53) 9 (14.8) 4.78 (2.33) 7 (17.1) 5.86 (1.86) 5 (14.3) 4.40 (2.70)

Depression 23 (9.5) 5.43 (1.67) 6 (9.8) 4.00 (4.77) 5 (12.2) 3.20 (2.59) 5 (14.3) 3.60 (2.88)

Comorbid 136 (56.4) 15.03 (4.13) 34 (55.7) 6.56 (6.08) 24 (58.5) 6.88 (6.15) 19 (54.3) 6.26 (5.88)

Nonclinical 56 (23.2) 5.05 (1.86) 12 (19.7) 4.58 (2.43) 5 (12.2) 6.00 (3.54) 6 (17.1) 3.67 (3.72)
PHQ-9b

Anxiety 26 (10.8) 6.81 (2.25) 9 (15) 3.89 (3.52) 7 (17.1) 3.29 (2.50) 5 (14.7) 3.00 (2.35)

Depression 26 (10.8) 12.91 (3.26) 6 (10) 6.83 (8.73) 5 (12.2) 6.40 (6.54) 5 (14.7) 6.80 (6.98)

Comorbid 136 (56.4) 17.37 (4.94) 33 (55) 8.33 (7.43) 24 (58.5) 8.79 (7.37) 19 (55.9) 8.00 (6.76)

Nonclinical 56 (23.2) 5.05 (2.54) 12 (20) 4.17 (2.52) 5 (12.2) 6.40 (3.21) 5 (14.7) 6.60 (5.41)
K-6c

Anxiety 26 (10.8) 12.92 (2.87) 9 (15) 9.78 (1.56) 7 (17.1) 10.00 (0.82) 5 (14.7) 8.40 (1.67)

Depression 23 (9.5) 15.04 (3.57) 6 (10) 11.83 (6.62) 5 (12.2) 12.00 (5.29) 5 (14.7) 12.20 (7.82)

Comorbid 136 (56.4) 20.53 (4.73) 33 (55) 13.24 (6.49) 24 (58.5) 11.92 (5.77) 19 (55.9) 11.21 (4.89)

Nonclinical 56 (23.2) 10.63 (2.73) 12 (20) 10.75 (2.56) 5 (12.2) 12.60 (5.22) 5 (14.7) 11.60 (5.03)
DERS-36d

Anxiety 26 (10.8) 95.88 (19.37) 9 (15.3) 79.00 (21.43) 7 (17.1) 73.71 (20.34) 5 (14.7) 70.00 (23.77)

Depression 23 (9.5) 92.04 (20.76) 6 (10.2) 70.17 (36.68) 5 (12.2) 81.80 (22.58) 5 (14.7) 74.00 (28.30)

Comorbid 136 (56.4) 114.21 (21.49) 32 (54.2) 85.63 (33.74) 24 (58.5) 81.04 (33.44) 19 (55.9) 74.79 (29.51)

Nonclinical 56 (23.2) 83.93 (23.07) 12 (20.3) 77.42 (21.38) 5 (12.2) 65.40 (16.56) 5 (14.7) 71.00 (7.97)
MHC-SFe

Anxiety 26 (10.8) 38.42 (11.93) 9 (15) 44.44 (10.69) 7 (17.1) 51.57 (10.21) 5 (14.7) 47.80 (13.29)

Depression 23 (9.5) 27.83 (11.01) 6 (10) 46.00 (21.42) 5 (12.2) 40.60 (18.81) 5 (14.7) 43.80 (17.12)

Comorbid 136 (56.4) 24.93 (12.14) 33 (55) 42.36 (20.02) 24 (58.5) 46.08 (17.43) 19 (55.9) 43.89 (19.64)

Nonclinical 56 (23.2) 41.95 (12.22) 12 (20) 46.17 (10.99) 5 (12.2) 36.40 (20.07) 5 (14.7) 32.80 (7.79)
R-LOTf

Anxiety 26 (10.8) 13.08 (4.99) 9 (15.3) 16.78 (4.27) 7 (17.1) 19.57 (3.05) 5 (14.7) 19.00 (5.39)

Depression 23 (9.5) 12.09 (3.60) 6 (10.2) 15.17 (5.88) 5 (12.2) 14.80 (3.96) 5 (14.7) 12.60 (4.98)

Comorbid 136 (56.4) 10.01 (4.99) 32 (54.2) 14.81 (6.76) 24 (58.5) 15.33 (6.15) 19 (55.9) 15.16 (5.01)

Nonclinical 56 (23.2) 13.71 (4.63) 12 (20.3) 14.83 (4.61) 5 (12.2) 15.40 (5.03) 5 (14.7) 15.40 (3.91)
ED-5D-3L Utility Index

Anxiety 26 (10.8) 0.77 (0.11) 9 (15.5) 0.88 (0.11) 7 (17.1) 0.79 (0.19) 5 (14.7) 0.86 (0.08)

Depression 23 (9.5) 0.75 (0.11) 6 (10.3) 0.77 (0.23) 5 (12.2) 0.87 (0.13) 5 (14.7) 0.74 (0.31)

Comorbid 136 (56.4) 0.61 (0.19) 31 (53.4) 0.77 (0.23) 24 (58.5) 0.81 (0.17) 19 (55.9) 0.79 (0.19)

Nonclinical 56 (23.2) 0.86 (0.14) 12 (20.7) 0.90 (0.11) 5 (12.2) 0.87 (0.12) 5 (14.7) 0.85 (0.23)
ED-5D-3L Health Rating

Anxiety 26 (10.8) 71.46 (10.89) 9 (15.5) 78.33 (10.31) 7 (17.1) 71.14 (28.82) 5 (14.7) 81.60 (11.63)

Depression 23 (9.5) 60.70 (16.16) 6 (10.3) 79.17 (18.28) 5 (12.2) 80.60 (11.15) 5 (14.7) 57.00 (34.74)

Comorbid 136 (56.4) 54.86 (21.41) 31 (53.4) 69.29 (23.46) 24 (58.5) 67.50 (24.16) 19 (55.9) 74.53 (17.11)

Nonclinical 56 (23.2) 75.55 (12.69) 12 (20.7) 78.75 (14.60) 5 (12.2) 62.80 (34.41) 5 (14.7) 76.40 (5.46)

aGAD-7: Generalized Anxiety Disorder 7.

bPHQ-9: Patient Health Questionnaire 9

cK-6: Kessler 6.

dDERS-36: Difficulties in Emotional Regulation 36.

eMHC-SF: Mental Health Continuum—Short Form.

fR-LOT: Revised Life Orientation Test.